BERLIN (dpa-AFX) - Bio-Techne Corp. (TECH), a life sciences company, announced Tuesday that it has won a second claim of reverse engineering by Miltenyi Biotec B.V. & Co. KG, which may appeal the ...

Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

Line” rating for Bio-Techne Corporation (TECH), placing a price target of $68 on the stock. This comes as a key moment for investors looking to evaluate the company’s potential given its current ...

Techne is a consortium of nine universities in London and the South East offering a rich and diverse training programme for doctoral students with a focus on interdisciplinarity and developing career ...

Bio-Techne Corp. topped $1 billion in full-year sales for the first time, its latest results showed Thursday, and the Minneapolis-based life science firm said it is beginning a two-year leadership ...

Bio-Techne Corp. Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. Its products assist scientific ...

The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...